Catalog No.
DHA30301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
ODF, TNF-related activation-induced cytokine, Osteoclast differentiation factor, TNFSF11, TRANCE, Osteoprotegerin ligand, RANKL, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa-B ligand, CD254, OPGL
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O14788
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AMG162, CAS: 615258-40-7
Clone ID
Denosumab
Stopping Denosumab, PMID: 30659428
Denosumab: A Review in Postmenopausal Osteoporosis, PMID: 29435849
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS, PMID: 28789921
A Review on the Role of Denosumab in Fracture Prevention, PMID: 33061307
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension, PMID: 28546097
Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures, PMID: 27862983
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials, PMID: 25639776
Bone Mineral Density After Transitioning From Denosumab to Alendronate, PMID: 31665314
Denosumab: a new agent in the management of hypercalcemia of malignancy, PMID: 26403973
Effects and management of denosumab discontinuation, PMID: 29317292
Denosumab: AHFS 92:24, PMID: 29864491
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis, PMID: 30071889
Denosumab for dialysis patients with osteoporosis: A cohort study, PMID: 32051451
Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials, PMID: 30535289
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study, PMID: 32716706
Denosumab cessation, PMID: 32487553
Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis, PMID: 31616133
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement, PMID: 28539165
Denosumab in the treatment of glucocorticoid-induced osteoporosis, PMID: 30019224
Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 32333877
Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial, PMID: 32459005
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma, PMID: 29052442
Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature, PMID: 30877429
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates, PMID: 31776637
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis, PMID: 31678488
Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis, PMID: 29672714
A comprehensive review of denosumab for bone metastasis in patients with solid tumors, PMID: 26451465
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study, PMID: 29631782
Off-label uses of denosumab in metabolic bone diseases, PMID: 31454537
Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial, PMID: 33057807
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study, PMID: 30508316
Denosumab in osteoporosis, PMID: 24289327
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study, PMID: 29694685
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab, PMID: 29573473
Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis, PMID: 31899506
Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials, PMID: 33145606
Denosumab for Reducing Risk of Fractures in Postmenopausal Women, PMID: 31038897
Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial, PMID: 30690785
Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review, PMID: 30854568
Certainties and Uncertainties About Denosumab Discontinuation, PMID: 29926143
Radiological findings of denosumab treatment for giant cell tumours of bone, PMID: 32335707
Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study, PMID: 27736041
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis, PMID: 32524500
Hypocalcaemia following denosumab in prostate cancer: A clinical review, PMID: 32017154
Effects of Denosumab After Treatment Discontinuation : A Review of the Literature, PMID: 29720299
Denosumab in Prevention of Implant Migration, PMID: 32609393
Adjuvant denosumab in early breast-cancer, PMID: 32135108
Adjuvant denosumab in early breast-cancer, PMID: 32135107
Aneurysmal bone cyst: results of an off label treatment with Denosumab, PMID: 31630689
Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients, PMID: 29616561
For research use only. Not for human or drug use.
